Next Century Growth Investors LLC Decreases Stake in Harrow, Inc. (NASDAQ:HROW)

Next Century Growth Investors LLC decreased its holdings in shares of Harrow, Inc. (NASDAQ:HROW - Free Report) by 25.0% in the fourth quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 125,520 shares of the company's stock after selling 41,940 shares during the period. Next Century Growth Investors LLC owned 0.35% of Harrow worth $4,211,000 at the end of the most recent reporting period.

Several other institutional investors and hedge funds have also bought and sold shares of HROW. Vanguard Group Inc. raised its holdings in shares of Harrow by 0.3% during the fourth quarter. Vanguard Group Inc. now owns 1,872,100 shares of the company's stock valued at $62,809,000 after acquiring an additional 5,225 shares in the last quarter. State Street Corp lifted its position in shares of Harrow by 2.2% in the 3rd quarter. State Street Corp now owns 730,973 shares of the company's stock worth $32,865,000 after purchasing an additional 15,554 shares during the period. Geode Capital Management LLC lifted its position in shares of Harrow by 0.6% in the 3rd quarter. Geode Capital Management LLC now owns 722,730 shares of the company's stock worth $32,500,000 after purchasing an additional 3,960 shares during the period. Charles Schwab Investment Management Inc. boosted its stake in shares of Harrow by 1.4% during the 4th quarter. Charles Schwab Investment Management Inc. now owns 255,218 shares of the company's stock valued at $8,563,000 after purchasing an additional 3,589 shares in the last quarter. Finally, JPMorgan Chase & Co. increased its position in shares of Harrow by 443.1% during the third quarter. JPMorgan Chase & Co. now owns 238,367 shares of the company's stock valued at $10,717,000 after buying an additional 194,480 shares during the period. Hedge funds and other institutional investors own 72.76% of the company's stock.

Harrow Stock Up 2.3 %

Shares of HROW stock traded up $0.54 during trading hours on Thursday, hitting $23.89. 94,121 shares of the company's stock traded hands, compared to its average volume of 506,866. The company has a quick ratio of 1.44, a current ratio of 1.55 and a debt-to-equity ratio of 3.23. The stock has a market cap of $851.67 million, a price-to-earnings ratio of -25.42 and a beta of 0.46. The stock's fifty day simple moving average is $26.44 and its two-hundred day simple moving average is $35.99. Harrow, Inc. has a 12-month low of $9.86 and a 12-month high of $59.23.

Harrow (NASDAQ:HROW - Get Free Report) last released its earnings results on Thursday, March 27th. The company reported $0.25 EPS for the quarter, topping analysts' consensus estimates of $0.11 by $0.14. The firm had revenue of $66.83 million for the quarter, compared to analysts' expectations of $66.01 million. Harrow had a negative return on equity of 45.57% and a negative net margin of 19.75%. On average, analysts expect that Harrow, Inc. will post -0.53 EPS for the current year.

Analyst Upgrades and Downgrades

Several brokerages have commented on HROW. HC Wainwright restated a "buy" rating and issued a $57.00 price objective on shares of Harrow in a report on Monday, March 31st. B. Riley lowered their target price on Harrow from $69.00 to $65.00 and set a "buy" rating for the company in a research note on Tuesday, April 1st.

Harrow Profile

Harrow, Inc operates as an ophthalmic-focused healthcare company. The company owns ImprimisRx, an ophthalmology outsourcing and pharmaceutical compounding business. The company was formerly known as Imprimis Pharmaceuticals, Inc and changed its name to Harrow Health, Inc in December 2018. Harrow Health, Inc was incorporated in 2006 and is headquartered in Nashville, Tennessee.